Understanding mode of action can drive the translational pipeline towards more reliable health benefits for probiotics

Simple item page
dc.contributor.authorKleerebezem, Michiel
dc.contributor.authorBinda, Sylvie
dc.contributor.authorBron, Peter A.
dc.contributor.authorGross, Gabriele
dc.contributor.authorHill, Colin
dc.contributor.authorvan Hylckama Vlieg, Johan E. T.
dc.contributor.authorLebeer, Sarah
dc.contributor.authorSatokari, Reetta
dc.contributor.authorOuwehand, Arthur C.
dc.contributor.funderILSI Europe Probiotics Task Forceen
dc.date.accessioned2019-10-01T05:11:39Z
dc.date.available2019-10-01T05:11:39Z
dc.date.issued2018-10-05
dc.description.abstractThe different levels of knowledge described in a translational pipeline (the connection of molecular mechanisms with pre-clinical physiological and human health effects) are not complete for many probiotics. At present, we are not in a position to fully understand the mechanistic basis of many well established probiotic health benefits which, in turn, limits our ability to use mechanisms to predict which probiotics are likely to be effective in any given population. Here we suggest that this concept of a translation pipeline connecting mechanistic insights to probiotic efficacy can support the selection and production of improved probiotic products. Such a conceptual pipeline would also provide a framework for the design of clinical trials to convincingly demonstrate the benefit of probiotics to human health in well-defined subpopulations.en
dc.description.statusPeer revieweden
dc.description.versionPublished Versionen
dc.format.mimetypeapplication/pdfen
dc.identifier.citationKleerebezem, M., Binda, S., Bron, P.A., Gross, G., Hill, C., van Hylckama Vlieg, J.E., Lebeer, S., Satokari, R. and Ouwehand, A.C., 2019. Understanding mode of action can drive the translational pipeline towards more reliable health benefits for probiotics. Current opinion in biotechnology, 56, (5pp). DOI:10.1016/j.copbio.2018.09.007en
dc.identifier.doi10.1016/j.copbio.2018.09.007en
dc.identifier.eissn1879-0429
dc.identifier.endpage60en
dc.identifier.issn0958-1669
dc.identifier.journaltitleCurrent Opinion in Biotechnologyen
dc.identifier.startpage55en
dc.identifier.urihttps://hdl.handle.net/10468/8645
dc.identifier.volume56en
dc.language.isoenen
dc.publisherElsevier Ltden
dc.relation.urihttps://www.sciencedirect.com/science/article/pii/S0958166918300910
dc.rights© 2018 The Authors. Published by Elsevier Ltden
dc.rights.urihttps://creativecommons.org/licenses/by-nc-nd/4.0/en
dc.subjectProbioticsen
dc.subjectHuman health effectsen
dc.subjectTranslation pipelineen
dc.titleUnderstanding mode of action can drive the translational pipeline towards more reliable health benefits for probioticsen
dc.typeArticle (peer-reviewed)en
Files
Original bundle
Now showing 1 - 1 of 1
Thumbnail Image
Name:
1-s2.0-S0958166918300910-main.pdf
Size:
599.12 KB
Format:
Adobe Portable Document Format
Description:
Published version
Download
License bundle
Now showing 1 - 1 of 1
Thumbnail Image
Name:
license.txt
Size:
2.71 KB
Format:
Item-specific license agreed upon to submission
Description:
Download
Collections
Microbiology - Journal Articles
APC Microbiome Ireland - Journal Articles